Recent 8-K filings for CURX

• October 19, 2026, 5:15 PM ET litigation materiality 0.75 negative item 8.01

  Curanex faces two putative securities class actions over August 2025 IPO disclosures

  Daymond Morales filed Action 1 on July 23, 2026 in New York Supreme Court (Index 159271/2026) against Curanex and underwriters Dominari, Pacific Century and Revere.

• September 4, 2026, 4:15 PM ET regulatory materiality 0.50 positive item 8.01

  Curanex regains Nasdaq minimum bid price compliance after 1-for-20 reverse split

  On Sept 3, 2026, Nasdaq confirmed closing bid price >= $1.00 for 10 straight business days (Aug 20-Sep 2).

• August 17, 2026, 4:45 PM ET other material materiality 0.50 neutral item 3.03item 5.03item 9.01

  Curanex Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 20, 2026

  1-for-20 reverse stock split effective 12:01 a.m. PT on Aug 20, 2026; Nasdaq trading begins split-adjusted that day.

• May 14, 2026, 9:15 AM ET other material materiality 0.60 positive item 7.01item 9.01

  Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis

  Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.

• May 7, 2026, 7:59 PM ET regulatory materiality 0.55 negative item 8.01

  Nasdaq grants CURX additional 180 days until Nov 2, 2026 to meet $1 bid price

  Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00; initial 180-day period ended May 4, 2026.

• April 2, 2026, 7:59 PM ET other material materiality 0.55 neutral item 7.01item 9.01

  Curanex expands drug pipeline to include cancer cachexia, a multi-billion-dollar market

  Company adds cancer cachexia as a new core indication beyond its six existing programs (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout).

• March 6, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 1.01item 5.02item 9.01

  Curanex Pharmaceuticals formalizes CEO/COO agreements; base salaries $393,600 and $180,000

  CEO Jun Liu: annual base salary $393,600, three-year term, plus $3,998/month auto lease.

• January 5, 2026, 6:59 PM ET leadership materiality 0.55 neutral item 5.02item 9.01

  Curanex CFO Haiyan Yang resigns; Wanjun Zhang appointed effective Jan 1, 2026

  Haiyan Yang resigned as CFO and Treasurer effective Dec 31, 2025; no disagreement cited.

• November 6, 2025, 6:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Curanex Pharmaceuticals receives Nasdaq bid price deficiency notice; 180-day cure period

  Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00 for 30 consecutive days.

• September 29, 2025, 7:59 PM ET other material materiality 0.55 positive item 3.02item 8.01item 9.01 ◈ Equity Issuances

  Curanex repays $408.5K in related-party loans, issues 28,312 shares for $200K

  Issued 28,312 shares to Xiaohong Song for $200,000 under amended subscription agreement; shares are 0.1% of total outstanding.

• September 12, 2025, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Curanex Pharma underwriters exercise full over-allotment; additional $2.25M raised

  Over-allotment option exercised in full; 562,500 shares at $4.00, raising additional $2.25M.

• August 27, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Curanex Pharmaceuticals closes IPO of 3.75M shares at $4.00, raising $15M gross

  Gross proceeds of $15M from IPO of 3,750,000 shares at $4.00 per share on firm commitment basis.

• August 26, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 8.01item 9.01

  Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M

  Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event other_material

5 positive 3 negative 5 neutral

source · CURX on sec.gov